BioUSA, the Grand Bell...Active Networking and Contract Performance of Korean Companies
Jun 20, 2025
|
Under the theme of "The world can't wait", this year's event in Boston, U.S., South Korea was the largest overseas visitor for the third consecutive year and operated the largest Korean pavilion ever involving 51 companies.
During this event (16th-19th), major bio companies such as Samsung Biologics, Celltrion, SK Biopharmaceuticals, Lotte Biologics, and Dong-A Socio Group set up their own booths.
Samsung Biologics reported that more than 150 meetings were held, while Celltrion reported that the number of pre-scheduled meetings alone exceeded last year's level with 110.
SK Biopharmaceuticals estimated that about 200 meetings took place, and Choi Yoon-jung, head of SK Biopharmaceuticals' business development division, is also known to have held several meetings.
Lotte Biologics, which was attended by Shin Yoo-yeol, head of Lotte Group's Future Growth Division, announced the news of a consignment production contract with bio company Otimo Pharma on the 18th, the third day of the event.
About 700 major domestic and foreign stakeholders, including global pharmaceutical companies, venture capital (VC), and investment banks (IB), participated in the 「Korea Night Reception" held by the Korea Biological Association and others, and networking among industry stakeholders was also actively carried out.
In particular, major domestic CDMO companies focused on strengthening their competitiveness drew attention.
Samsung Biologics, which has the largest global production capacity, drew attention when CEO John Lim announced at a press conference that he would maximize production capacity by building a third bio campus and declared his entry into the organoid business 'mini long-term model'. Celltrion, which used to focus on biosimilars (biopharmaceutical generic drugs), focused on promoting the competitiveness of new drugs. Lotte Biologics announced the competitiveness of Syracuse Bio-Campus and Songdo Bio-Campus.
Roh Yeon-hong, Chairman of the Korea Pharmaceutical Bio Association, confirmed that the Korean pharmaceutical bio industry's status on the global stage is soaring through the participation in Bio USA," he said.
This article was translated by Naver AI translator.
